Page last updated: 2024-12-05

2,4-xylidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-xylidine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,4-dimethylaniline : A primary arylamine that is aniline in which the hydrogens at the 2- and 4-positions are replaced by methyl groups. A clear to yellow liquid, it is used in production of certain dyes, pesticides and other chemicals. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7250
CHEMBL ID1490826
CHEBI ID27840
SCHEMBL ID33980
MeSH IDM0054603

Synonyms (90)

Synonym
asym-m-xylidene
CHEBI:27840 ,
2,4-dimethyl-phenylamine
2,4-xylylamine
2,4-dimethylbenzeneamine
2,4-dimethylbenzene-1-amine
2,4-dimethylbenzenamine
nsc7640
4-amino-1,3-dimethylbenzene
1-amino-2,4-dimethylbenzene
nsc-7640
aniline,4-dimethyl-
wln: zr b1 d1
m-4-xylidine
4-amino-1,3-xylene
4-methyl-o-toluidine
2-methyl-p-toluidine
m-xylidine
4-amino-3-methyltoluene
inchi=1/c8h11n/c1-6-3-4-8(9)7(2)5-6/h3-5h,9h2,1-2h
benzenamine, 2,4-dimethyl-
NCGC00091885-01
brn 0636243
einecs 202-440-0
meta-xylidine
2,4-dimethylphenylamine
hsdb 2092
aniline, 2,4-dimethyl-
nsc 7640
m-xylidine (van)
ccris 254
ai3-16558
2,4-dimethylaniline
95-68-1
2,4-dma
2,4-xylidine
2,4-dimethylaniline, analytical standard
2,4-dimethylaniline, 98%
2,4-dimethylaniline, >=99%
STK387111
AC-10693
D0667
smr001307301
MLS002302982 ,
2,4-dimethyl aniline
AKOS000119112
NCGC00091885-02
NCGC00091885-03
HMS3039A03
dtxsid8026305 ,
NCGC00257934-01
dtxcid206305
tox21_200380
cas-95-68-1
4-amino-m-xylene
unii-367r1l22c9
367r1l22c9 ,
4-12-00-02545 (beilstein handbook reference)
ec 202-440-0
FT-0610166
2,4-xylidine [iarc]
xylidine 2,4-dimethylbenzenamine [mi]
xylidine 2,4-dimethylbenzenamine
2,4-xylidine [hsdb]
2,4-dimethylaniline [usp impurity]
CHEMBL1490826
[2,4,5-tris(acetoxymethyl)cyclohexyl]methyl acetate
SCHEMBL33980
cid_7250
bdbm74411
2,4-dimethylphenyl amine
(2,4-dimethylphenyl)amine
2,4-dimethyl-aniline
2,4 xylidine
2,4-dimethylphenyl-amine
STR00897
W-109655
mfcd00007738
51S ,
J-507242
F2190-0463
2,4-dimethylaniline; amitraz imp. a (bp); 2,4-xylidine; amitraz impurity a
2,4-dimethylaniline 100 microg/ml in acetonitrile
2,4-dimethylaniline (2,4-xylidine)
2,4-dimethylaniline 10 microg/ml in cyclohexane
1071170-27-8
EN300-17981
3-(3-(2-(4-chlorophenylsulfonamido)ethyl)-5-(4-fluorobenzyl)phenyl)propanoic acid
2,4-xylidine-d6
Z57127436
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
dimethylanilineA methylaniline carrying at least two methyl groups.
primary arylamineA primary amine formally derived from ammonia by replacing one hydrogen atom by an aryl group. R-NH2 where R is an aryl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.53820.006038.004119,952.5996AID1159521
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.95720.003041.611522,387.1992AID1159552
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency44.66840.001024.504861.6448AID588534
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ORF73Human gammaherpesvirus 8EC50 (µMol)75.00000.06008.134632.1400AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (12.90)18.7374
1990's2 (6.45)18.2507
2000's15 (48.39)29.6817
2010's9 (29.03)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.61 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]